Zai Lab Stock News

Zai Lab (NASDAQ:ZLAB) had its price target boosted by Citigroup from $217.00 to $231.00 in a research report sent to investors on Friday morning, The Fly reports. The firm currently has a buy rating on the stock. A number of other brokerages also recently weighed in on ZLAB. SVB Leerink cut their price target on []

Baillie Gifford & Co. lifted its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB) by 21.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,895,281 shares of the companys stock after purchasing an additional 853,991 shares during the quarter. Baillie []

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA) has been updated to include ZEJULA (niraparib) as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) following a response to platinum-based chemotherapy, regardless of biomarker status.

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date peri

Zai Lab Limited (NASDAQ:ZLAB) traded at $69.25 at close of the session on Tuesday, 11/30/21, made a downward move of -4.36% on its previous days price. Looking at the stock we see that its previous close was $72.41 and the beta (5Y monthly) reads 1.10 with the days price range being $67.77 $74.08. In Are Investors Declined To Sell Their Zai Lab Limited (NASDAQ: ZLAB) Holdings? Read More »

•   PRIME study demonstrates that niraparib treatment had a clinically meaningful and statistically significant benefit in improving progression-free survival in the overall study population reg

PRIME study demonstrates that niraparib treatment had a clinically meaningful and statistically significant benefit in improving progression-free survival in the overall study population regardless of biomarker status when compared to placebo

The stock price of Zai Lab Ltd (NASDAQ: ZLAB) increased by over 2% during intraday trading today. This is why it happened.

Hamilton Lane Advisors LLC bought a new stake in shares of Zai Lab Limited (NASDAQ:ZLAB) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 9,737 shares of the companys stock, valued at approximately $1,026,000. Other hedge funds have also added to or reduced their stakes []

During the last session, Zai Lab Limited (NASDAQ:ZLAB)s traded shares were 0.55 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stocks price was $75.83, reflecting an intraday gain of 5.47% or $3.93. The 52-week high for the ZLAB share is $193.54, that puts it down Is Zai Lab Limited (NASDAQ: ZLAB) Hit More of the Losses Given A -155.23% Dip From High? Read More »

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in December:

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical co

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutic